6 psychedelic stocks to watch

For many investors, the experimental psychedelics industry may be too risky to invest in. Most companies in this sector are privately held, and psychedelic stocks are often volatile penny or OTC stocks.

Aside from being risky, these stocks can also be difficult to purchase. Most stocks will require you to have a brokerage account that offers access to OTC and international stocks, like Interactive Brokers.

For investors willing to take the risk, the best psychedelic stocks depend on your portfolio and investment goals—while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.

6 popular psychedelic stocks to watch

We round up a selection of stocks in or related to the experimental drug industry, weighting the list more heavily towards popular mid- and large-cap stocks.

Best stock	1-year return	Market cap	Exchange	Volume	Buy on Questrade
Compass Pathways Plc (CMPS.US)	110.75% Compass Pathways Plc's 1-year return based on the closing price as of November 5, 2025.	$1.6 billion (USD)	NASDAQ	2,180,332	Buy now
Definium Therapeutics (DFTX.US)	183.61% Definium Therapeutics's 1-year return based on the closing price as of November 5, 2025.	$5.1 billion (USD)	NASDAQ	1,413,138	Buy now
Cybin (HELP.US)	45.88% Cybin's 1-year return based on the closing price as of November 5, 2025.	$797.1 million (USD)	NASDAQ	1,239,360	Buy now
ATAI Life Sciences BV (ATAI.US)	64.06% ATAI Life Sciences BV's 1-year return based on the closing price as of November 5, 2025.	$2.7 billion (USD)	NASDAQ	(data unavailable)	Buy now
Psyched Wellness (PSYC.CN)	-66.67% Psyched Wellness's 1-year return based on the closing price as of November 5, 2025.	$2 million (CAD)	Canadian Securities Exchange	27,000	Buy now
Field Trip Health (FTRP.CN)	(data unavailable)	$210.8 million (CAD)	Canadian Securities Exchange	(data unavailable)	Buy now

The values in this table are accurate as of the market close on October 29, 2026, or the most recent data available. Volume refers to the number of shares traded during the day.

What to look for when investing in psychedelic stock

The experimental drug industry is affected by a range of complex factors such as trade policies, regulations, and fluctuating supply and demand. So when considering psychedelic stocks to buy, it's important that you have access to vital information about a company's financial health, leadership team, and market positioning.

Also keep in mind that, while volatility can be ideal for day traders, long-term investors will want to look for stocks to offer steadier gains over time.

How to invest in psychedelic stock

1. Research the experimental drug industry. Before investing, learn about the psychedelic stock sector, its trends and the companies within it. Look at each company's financial health, potential for growth and past performance to identify stocks that fit your investment goals.
2. Choose a stock trading platform. Compare trading fees, access to trading tools and user interface options. We've identified reliable trading platforms to help narrow down your options below or check out the best stock trading apps in Canada to find one that suits your needs.
3. Open and fund your account. Sign up with your personal details and link a bank account or funding method to deposit money before you start trading.
4. Select the psychedelic stock(s) to buy. Search by company name or ticker symbol, like CMPS or DFTX. Compare key metrics such as market cap, price history and earnings per share to pick the best stock for your strategy.
5. Buy the stock and monitor performance. Place your order to buy the stock and track its performance over time. Consider setting alerts, signing up for industry newsletters or using platform research tools to stay up to date on market changes.

Our top picks for where to buy psychedelic stocks

Are psychedelic stocks a good investment?

While it's possible to turn a profit investing in psychedelic stocks, keep in mind that—like any investment—psychedelic stocks are not immune to risk. These stocks are subject to fluctuating conditions both in the market and in the experimental drug industry, so carefully vet your picks before you invest.

What are the best psychedelic stocks?

A lot of factors go into picking the best psychedelic stocks. Stock performance can be impacted by factors like market conditions, company decisions and global events. Plus, what may be a strong psychedelic stock investment for one person might not be suitable for another.

That said, we rounded up this list of popular psychedelic stocks in or related to the experimental drug industry to help narrow down your options:

• Compass Pathways Plc (CMPS)
• Definium Therapeutics (DFTX)
• Cybin (HELP)
• ATAI Life Sciences BV (ATAI)
• Psyched Wellness (PSYC)
• Field Trip Health (FTRP)

Keep in mind that this is not a "best" list or a recommendation. It highlights some psychedelic stocks for informational purposes only and does not indicate past or future performance or investment advice. We do not guarantee any investment performance.

We've outlined detailed company and stock performance details for each psychedelic stock below. Keep reading to decide if any of these companies are the right investment for you.

---

Compass Pathways Plc (CMPS)

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.

The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.

Closing stock price	$11.57
Market Capitalization The total market value of Compass Pathways Plc's outstanding shares	$1.6 billion
Earnings per share (TTM)	-$3.76
52-week stock price range	$4.88 – $15.87

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on October 29, 2026.

---

Definium Therapeutics (DFTX)

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.

The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.

Closing stock price	$32.70
Market Capitalization The total market value of Definium Therapeutics's outstanding shares	$5.1 billion
Earnings per share (TTM)	-$3.43
52-week stock price range	$10.47 – $49.70

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on November 3, 2026.

---

Cybin (HELP)

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders.

The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system.

Closing stock price	$8.68
Market Capitalization The total market value of Cybin's outstanding shares	$797.1 million
Earnings per share (TTM)	-$4.15
52-week stock price range	$3.76 – $15.15

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on November 3, 2026.

---

ATAI Life Sciences BV (ATAI)

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments. The company develops rapid-acting and durable therapies for conditions with limited treatment options.

Its pipeline includes BPL-003 (mebufotenin benzoate), an intranasal formulation in Phase 2 and 3 clinical studies for treatment-resistant depression and alcohol use disorder; ELE-101, a serotonergic psychedelic for major depressive disorder; and RL-007, an orally bioavailable pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia.

Closing stock price	$7.35
Market Capitalization The total market value of ATAI Life Sciences BV's outstanding shares	$2.7 billion
Gross profit (TTM)	$-70,624,000
Revenue (TTM)	$4.5 million
Earnings per share (TTM)	-$2.79
52-week stock price range	$3.27 – $7.45

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on September 10, 2026.

---

Psyched Wellness (PSYC)

Psyched Wellness Ltd. produces and distributes mushroom-derived products and related consumer packaged goods in the United States. It offers a line of Amanita Muscaria-derived extracts to promote stress relief, relaxation, and assist with restful sleeping.

The company sells its products online.

Closing stock price	C$0.01
Market Capitalization The total market value of Psyched Wellness's outstanding shares	C$2 million
Gross profit (TTM)	C$179,679
Revenue (TTM)	C$775,142
Earnings per share (TTM)	-C$0.02
52-week stock price range	C$0.01 – C$0.02

All dollar amounts in this table are in CAD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on November 1, 2026.

---

Field Trip Health (FTRP)

Field Trip Health Ltd. engages in the development and delivery of psychedelic therapies. Its Research division is involved in the development of psychedelic molecules and conducting research on plant-based psychedelics.

The company also operates Field Trip Health clinics for psychedelic therapies in North America.

Market Capitalization The total market value of Field Trip Health's outstanding shares	C$210.8 million
Gross profit (TTM)	C$-8,403
Revenue (TTM)	C$435,460

All dollar amounts in this table are in CAD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on .

Compare trading platforms to buy psychedelic stock

Compare special offers, low fees and a wide range of investment options among popular trading platforms in Canada. Note that the dollar amounts in the table below are in CAD.

Related: Compare the best stock trading platforms in Canada

Bottom line

If you're considering adding psychedelic stocks to your portfolio, make sure you thoroughly look into any companies before investing to help mitigate risk. We've compiled a list of psychedelic stocks to help narrow down your options. Then choose a legitimate stock trading platform to start investing. After that it comes down to monitoring the experimental drug industry to know when to buy, sell or hold. How to buy stocks in Canada

Frequently asked questions about psychedelic stocks

• What are psychedelic stocks?

  Psychedelic stocks are shares of companies that either directly work in the psychedelic sector or operate within related industries. Investors interested in buying psychedelic stocks may be looking to take advantage of market trends or lock in investments for the long haul.

• What is the top psychedelic stock to buy in 2026?

  Unfortunately, it's almost impossible to choose a single "top" psychedelic stock to invest in due to factors like market fluctuations, company management and shifting economic trends. These can all change—sometimes overnight—how a stock performs. It's best to do your own research to decide which companies fit within your risk tolerance. Reviewing a company's financial reports and past stock performance can help you decide if it's worth investing in.

• Where can I find information and regular updates about the experimental drug industry?

  You can keep track of the latest experimental drug news and updates by signing up for financial newsletters, visiting financial news sites, reading company investor relations pages and using market research platforms. Many online brokerages also offer sector reports, stock screeners and alerts to help you track movements in your stock performance or updates in or related to the experimental drug industry.

Check these other commodities and investment sectors

If you're thinking about diversifying your portfolio and investing in sectors beyond psychedelic stocks, here are some others you can consider:

Important information: Powered by Finder.com. This information is general in nature and is no substitute for professional advice. It does not take into account your personal situation. This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for most investors. You do not own or have any interest in the underlying asset. Capital is at risk, including the risk of losing more than the amount originally put in, market volatility and liquidity risks. Past performance is no guarantee of future results. Tax on profits may apply. Consider the Product Disclosure Statement and Target Market Determination for the product on the provider's website. Consider your own circumstances, including whether you can afford to take the high risk of losing your money and possess the relevant experience and knowledge. We recommend that you obtain independent advice from a suitably licensed financial advisor before making any trades.